Echo Therapeutics, Inc., a diabetes management company developing a new needle-free Glocose Monitoring System, reports starting a new a clinical study of its Symphony(TM) Transdermal Continuous Glucose Monitoring product. The (tCGM System) study includes patients with Type 1 and Type 2 diabetes. The purpose of the study is to test the performance of its new one-piece, cost-effective biosensor. Echo expects to announce completed results of the study by the fourth quarter of 2009.

Echo’s pilot clinical study will enroll patients that have either type 1 or type 2 diabetes and will compare data obtained from its Symphony tCGM System with data from the “YSI Glucose Analyzer. The study will obtain about 900 data pairs for use in the analyses. The study will be blind to participating subjects and personnel working on the project and will include reference glucose measurements made at roughly 15 minute intervals for 24 hours.

Patrick T.

...

DaVita Inc. (DVA) reported third quarter net income of $110.9 million or $1.06 per share, which was better than the Zacks Consensus Estimate of 99 cents. The company earned $93.9 million or 89 cents in the comparable quarter of 2008.  Revenues for the quarter came in at $1.57 billion, which reflected an 8.3% increase over the year-ago quarter. According to segments, revenues from the Dialysis and Related Lab Services segment for the quarter came in at $1.49 billion as against $1.38 billion in the prior-year quarter. Other - Ancillary Services and Strategic Initiatives segment generated revenues of $83 million as against $69 million in the year-ago quarter. Highlights of the strong display in the reported quarter included consistent volume growth, stable private pricing and strong cash flows.  Total treatments for the quarter came in at approximately 4.34 million, or 54,927 treatments per day, representing a per ...


The Procter & Gamble Company (PG) reported results for the first quarter of fiscal 2010 with earnings of 97 cents per share, in line with the Zacks Consensus Estimate but down 5.8% year-over-year. Net sales for the quarter declined 5.6% year-over-year to $19.8 billion, as a 3% benefit from pricing and 1% benefit from product mix was fully offset by a 3% decline in unit volume -- a 7% unfavorable impact of foreign currency and a 1% impact of divestitures. However, successful product launches, supported by marketing initiatives, contributed to the top line. Organic sales grew 2% during the quarter driven by pricing and product mix. All three Global Business Units (GBU) witnessed revenue declines during the quarter. The Beauty segment declined 5%, with the low single-digit growth in retail hair care volumes offset by the double-digit decline in Professional salon volume and mid-single-digit decline in female ...

Bayer (BAYRY) announced its third quarter results yesterday. Revenues of the group recorded a 7% decline to €7.39 billion from €7.94 billion. The company’s earnings per share from continued operations were €0.78, compared to €0.85 in year-ago period.

Bayer operates through three major segments: Healthcare, accounting for 53.24% of total revenues in the third quarter of 2009; CropScience (15.4%), and Material Science (27.5%) with the remaining 4% coming from other items. While Healthcare segment revenues improved marginally by 3.5%, both cropscience and Material Science fell 8.6% and 20%, respectively.

The Healthcare segment recorded revenues of €3.9 billion compared to €3.8 billion in the corresponding period last year. Both the divisions of Healthcare – pharmaceuticals and consumer health contributed to the growth of the Healthcare segment. Bayer’s primary market, Europe – accounting for 39% of its Healthcare revenues – declined 3%, compared to the year-ago period. The other markets of North America,

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 26, 2009

DrStockPick.com Stock Report!

PWRM, BCRX

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical

...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

DrStockPick.com Watch List!

My Picks for Monday October 26, 2009, are:

**************************************************************

BCRX, BioCryst Pharmaceuticals, Inc.

U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said on Saturday.

BCRX designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases. BCRX has progressed two novel compounds into late-stage pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma

The U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention,

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Saturday October 24, 2009

DrStockPick.com Stock Report!

**************************************************************

U.S. President Barack Obama has declared 2009 H1N1 swine flu a national emergency, the White House said on Saturday.

________________________________________________

BCRX, BioCryst Pharmaceuticals, Inc.

BCRX designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer and inflammatory diseases.  BCRX has progressed

...

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

...

Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2.

Company Description

Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States.

The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development.

Third Quarter Zacks Consensus Estimate Rises

As the third quarter earnings report scheduled for Nov 5 approaches, analysts are becoming more bullish on Par.

In just the last week, 3 out of 8 covering analysts have raised estimates by 3 cents to 47 cents per share. That is a 74% increase in the estimate in the last 3 months.

The full year Zacks Consensus

...

CBS Corporation (CBS), the media conglomerate, recently asserted that it still expects its full year 2009 operating income before depreciation and amortization (OIBDA) in the range of $1.725 billion to $1.925 billion.  The uptrend seen in the second-quarter 2009 revenue has made management optimistic and forecasted better results in the third and fourth quarters compared to the earlier quarters in 2009. The company also indicated some signs of revival in advertising demand in core categories like retail, telecom, pharmaceuticals and quick service restaurants.   Although the sluggish advertising market continues to hurt total revenue, which declined 11% to $3,006.3 million in the second-quarter 2009, but CBS saw a 3% improvement in quarterly revenue compared with a 14% drop in the first-quarter 2009.  In a separate story, National Amusement Inc., the holding company of media tycoon Sumner Redstone plans to sell its stake in CBS Corporation and ...